Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 programme. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active form of protein inhibitor 1 (I-1c) designed to block the action of protein phosphatase 1. Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.
April 17 (Reuters) - A key expert witness in lawsuits claiming that Syngenta's herbicide paraquat causes Parkinson's disease cannot testify in court, a federal judge ruled Wednesday, dismissing the first four cases over the product that were set to go to trial
Bayer`s patent for blood thinner Xarelto invalid, UK court rules
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, has named Mansuo Shannon, PhD as the company’s next Chief Scientific Officer (CSO).
Dr.Reddy's Laboratories said entered into a partnership agreement with Bayerto market and distribute a second brand of Vericiguat in India.
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million
As it works toward improving the diversity of its workforce, Bayer took a moment this week to celebrate some of the diverse voices already on board—and its efforts to uphold their rights.